HOUSE-BILL 1414: H.R.1414 - Cameron’s Law
AI-Powered Summary
HOUSE-BILL 1414 aims to restore the orphan drug tax credit from 25% to 50%, thereby incentivizing pharmaceutical companies to develop treatments for rare diseases. This legislation addresses economic rights and access to healthcare, potentially improving the availability of necessary medications for individuals with rare diseases. Key provisions include amending the Internal Revenue Code to enhance the orphan drug tax credit, with an effective date for taxable years beginning after the enactment of the Act. While the bill does not present significant constitutional concerns, it raises questions about government intervention in the pharmaceutical market and its alignment with free market principles. The restoration of the tax credit is expected to positively impact public health by increasing access to treatments, although scrutiny may arise regarding its equitable distribution among different populations.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill's restoration of the orphan drug tax credit is a significant step towards improving healthcare access for individuals with rare diseases, which can be seen as a fulfillment of the government's responsibility to protect public health. This aligns with constitutional principles that support the welfare of citizens.
Key Individual Rights
Right
Right to Health
Impact
Positive
Description
The bill may enhance access to medical treatments for individuals suffering from rare diseases, thereby supporting their right to health.
Right
Equal Protection
Impact
Potentially Negative
Description
If the benefits of the tax credit disproportionately favor certain demographic groups, it could raise concerns regarding equal access to healthcare.
Constitutional Provisions
- Taxing and Spending Clause (Article I, Section 8)
- Equal Protection Clause (14th Amendment)
Potential Constitutional Challenges
While the bill supports public health initiatives, there may be challenges regarding whether the benefits are equitably distributed among different demographic groups. If the pharmaceutical industry focuses on conditions affecting wealthier populations, this could lead to disparities in healthcare access, raising equal protection concerns.
Summary
HOUSE-BILL 1414 aims to enhance the development of treatments for rare diseases through a significant increase in the orphan drug tax credit. While it has the potential to positively impact individuals' health outcomes, particularly those with rare diseases, careful consideration must be given to ensure equitable access to the benefits it seeks to promote. The bill aligns with constitutional principles related to health and welfare but raises important questions about equal protection and access to healthcare.
Constitutional Analysis
This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention H.R. 1414 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreePolicy Topics
Timeline
February 18, 2025
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat